Virtual Target Screening: Validation Using Kinase Inhibitors

Computational methods involving virtual screening could potentially be employed to discover new biomolecular targets for an individual molecule of interest (MOI). However, existing scoring functions may not accurately differentiate proteins to which the MOI binds from a larger set of macromolecules in a protein structural database. An MOI will most likely have varying degrees of predicted binding affinities to many protein targets. However, correctly interpreting a docking score as a hit for the MOI docked to any individual protein can be problematic. In our method, which we term "Virtual Target Screening (VTS)", a set of small drug-like molecules are docked against each structure in the protein library to produce benchmark statistics. This calibration provides a reference for each protein so that hits can be identified for an MOI. VTS can then be used as tool for: drug repositioning (repurposing), specificity and toxicity testing, identifying potential metabolites, probing protein structures for allosteric sites, and testing focused libraries (collection of MOIs with similar chemotypes) for selectivity. To validate our VTS method, twenty kinase inhibitors were docked to a collection of calibrated protein structures. Here, we report our results where VTS predicted protein kinases as hits in preference to other proteins in our database. Concurrently, a graphical interface for VTS was developed.

[1]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[2]  J. Zheng,et al.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[3]  Adrian H Elcock,et al.  Progress toward virtual screening for drug side effects , 2002, Proteins.

[4]  F. Almeida,et al.  Implications of protein conformational diversity for binding and development of new biological active compounds. , 2006, Current medicinal chemistry.

[5]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[6]  Miklos Feher,et al.  Consensus scoring for protein-ligand interactions. , 2006, Drug discovery today.

[7]  G. Klebe,et al.  Statistical potentials and scoring functions applied to protein-ligand binding. , 2001, Current opinion in structural biology.

[8]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[9]  M. Milik,et al.  Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.

[10]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[11]  Bryan L. Roth,et al.  Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery , 2005, Nature Reviews Drug Discovery.

[12]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[13]  Robert P. Sheridan,et al.  Multiple protein structures and multiple ligands: effects on the apparent goodness of virtual screening results , 2008, J. Comput. Aided Mol. Des..

[14]  Adrian H Elcock,et al.  Structure selection for protein kinase docking and virtual screening: homology models or crystal structures? , 2006, Current protein & peptide science.

[15]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[16]  Sean Ekins,et al.  The importance of discerning shape in molecular pharmacology. , 2009, Trends in pharmacological sciences.

[17]  T. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[18]  Bernard R. Brooks,et al.  CHARMMing: A New, Flexible Web Portal for CHARMM , 2008, J. Chem. Inf. Model..

[19]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[20]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[21]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[22]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[23]  C. Lyle,et al.  Inhibition of Cell Proliferation and Cell Cycle Progression by Specific Inhibition of Basal JNK Activity , 2004, Journal of Biological Chemistry.

[24]  T. Halgren Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .

[25]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..

[26]  J. Kuriyan,et al.  c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.

[27]  Michael Karpusas,et al.  Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. , 2010, Biochemistry.

[28]  Sai Lakshmana Vankayala,et al.  Substitution of aminomethyl at the meta-position enhances the inactivation of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. , 2008, Journal of medicinal chemistry.

[29]  Sui Yung Chan,et al.  Monitoring drug-protein interaction. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[30]  G. Vigers,et al.  Multiple active site corrections for docking and virtual screening. , 2004, Journal of medicinal chemistry.

[31]  B. Chauffert,et al.  EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib , 2012, International journal of cancer.

[32]  Francesco L Gervasio,et al.  The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. , 2012, Journal of the American Chemical Society.

[33]  L. Meijer,et al.  Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.

[34]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[35]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[36]  Maria I. Zavodszky,et al.  Scoring confidence index: statistical evaluation of ligand binding mode predictions , 2009, J. Comput. Aided Mol. Des..

[37]  R. Hartmann,et al.  Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. , 2007, Journal of medicinal chemistry.

[38]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[39]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[40]  Alexander D. MacKerell,et al.  Computational Fragment-Based Binding Site Identification by Ligand Competitive Saturation , 2009, PLoS Comput. Biol..

[41]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[42]  E. Goldsmith,et al.  Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[43]  R. Margolis,et al.  SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition , 2010, Oncogene.

[44]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[45]  Steven J. M. Jones,et al.  A Computational Approach to Finding Novel Targets for Existing Drugs , 2011, PLoS Comput. Biol..

[46]  Y. Z. Chen,et al.  Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.

[47]  Aurélien Grosdidier,et al.  Docking, virtual high throughput screening and in silico fragment-based drug design , 2009, Journal of cellular and molecular medicine.

[48]  Didier Rognan,et al.  Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..

[49]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[50]  Thomas A. Halgren,et al.  Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..

[51]  Thomas A. Halgren,et al.  Merck molecular force field. IV. conformational energies and geometries for MMFF94 , 1996 .

[52]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[53]  Daniel Rauh,et al.  Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. , 2009, Journal of the American Chemical Society.

[54]  J. Willem M. Nissink,et al.  Simple Size-Independent Measure of Ligand Efficiency , 2009, J. Chem. Inf. Model..

[55]  S. Holbeck,et al.  Update on NCI in vitro drug screen utilities. , 2004, European journal of cancer.

[56]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[57]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[58]  W A Hendrickson,et al.  Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three‐dimensional structure. , 1990, The EMBO journal.

[59]  Jérôme Hert,et al.  Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..

[60]  M. Boguski,et al.  Repurposing with a Difference , 2009, Science.

[61]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[62]  Thomas Lengauer,et al.  Improved cyclodextrin-based receptors for camptothecin by inverse virtual screening. , 2007, Chemistry.

[63]  T. Halgren,et al.  Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules , 1996 .

[64]  Yi Wang,et al.  DITOP: drug-induced toxicity related protein database , 2007, Bioinform..

[65]  Mathias Dunkel,et al.  SuperDrug: a conformational drug database , 2005, Bioinform..

[66]  Sean Ekins,et al.  Reengineering the pharmaceutical industry by crash-testing molecules. , 2005, Drug discovery today.